Skip to main content

Adjuvant therapy of HER2+ breast cancer

Adjuvant therapy of HER2+ breast cancer has evolved dramatically over the past 4 years. It is now widely appreciated that treatment with trastuzumab, when administered concurrently or sequentially with chemotherapy, will decrease the risk of disease recurrence by approximately 50%. Clinical trials have also demonstrated a modest improvement in overall survival, and it is anticipated that this survival advantage will increase with further follow-up. Nevertheless, there are patients who will experience disease recurrence in spite of optimal trastuzumab-based therapy, and new treatment approaches are needed for these individuals. The results of the initial randomized trials have also given rise to a number of difficult questions that clinicians and patients face on a daily basis. The presentation will focus on controversial topics in the adjuvant treatment of HER2+ disease, including: the treatment of small, node-negative tumors; the uncertainty surrounding intermediate HER2+ test results; and the concerns about cardiac toxicity. New treatment approaches for HER2+ breast cancer that hold promise for the adjuvant setting will also be discussed.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Winer, E. Adjuvant therapy of HER2+ breast cancer. Breast Cancer Res 11, S13 (2009). https://doi.org/10.1186/bcr2274

Download citation

Keywords

  • Breast Cancer
  • Clinical Trial
  • Cancer Research
  • Trastuzumab
  • Adjuvant Therapy